Dendritic cell-based immunotherapy in acute and chronic myeloid leukaemia.
Persistence of residual leukaemia cells in acute and chronic myeloid leukaemia will eventually lead to a relapse of the disease. Dendritic cell-based vaccines might constitute a therapeutic option for leukaemia patients to control or eradicate minimal residual disease. Dendritic cells have the unique property to stimulate naïve T cells. In a majority of the myeloid leukaemia patients these cells can be generated directly from leukaemia cells, although several factors hamper the feasibility of this approach. Other options are being explored to make active specific DC-based immunotherapy in leukaemia more broadly applicable. This review summarises data on active specific DC-based immunotherapy in acute and chronic myeloid leukaemia and discusses current optimisation strategies.
Westers
Theresia M
TM
Department of Haematology, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. tm.westers@vumc.nl
Ossenkoppele
Gert J
GJ
van de Loosdrecht
Arjan A
AA
D000208:Acute Disease; D019496:Cancer Vaccines / Q000276:immunology; D002908:Chronic Disease; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007951:Leukemia, Myeloid / Q000628:therapy*
D019496:Cancer Vaccines